The Naples RoundtableTM Amicus Committee is responsible for making recommendations to the Officers and Advisory Board for action to be taken regarding issues before the courts in the United States. The Committee’s actions with respect to matters before the Federal Circuit is exclusive and independent of the Advisory Board, as well as anyone attending or participating in the Naples Roundtable or the Leahy Institute of Advanced Patent Studies.
Andrew S. Baluch, Chair
Hon. Sharon R. Barner
Hon. Q. Todd Dickinson
Teresa M. Summers
As early as 2016, the Amicus Committee identified Helsinn Healthcare, S.A., v. Teva Pharmaceuticals USA as a case of exceptional importance meriting the organization’s scholarly input. The case involves an issue of first impression regarding the AIA’s first-inventor-to-file provision in 35 U.S.C. § 102(a): whether an inventor’s sale of an invention to a third party that is obligated to keep the invention confidential qualifies as prior art. Prior to any appellate decision in the case, the Naples Roundtable filed an amicus brief in the Federal Circuit in 2016 urging the original Federal Circuit merits panel to consider Congress’ twin goals in adopting a first-inventor-to-file regime of achieving (a) greater international harmonization with other countries and (b) greater certainty regarding the scope of patent protection. After the petitioner filed a petition for writ of certiorari to the Supreme Court, the Naples Roundtable filed a cert-stage amicus brief in April 2018 urging the Supreme Court to grant the petition. In June 2018, the Supreme Court agreed with the Naples Roundtable and granted the petition. In August 2018, the Naples Roundtable filed a merits-stage amicus brief in support of neither party, which, among other things, brought to the Court’s attention the laws of other countries that do not treat such sales as prior art.